Biofrontera- Warrants (27/10/2026) Overview
Valuation check: BFRIW's ROE is -106.87%, below the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow-106.87%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Biofrontera- Warrants (27/10/2026) (BFRIW) currently reports a ROE of -106.87%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Biofrontera- Warrants (27/10/2026)'s ROE history and peer comparisons.
Biofrontera- Warrants (27/10/2026)'s ROE of -106.87% is lower than the Healthcare sector average of 21.67%. That is roughly 593.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Biofrontera- Warrants (27/10/2026)'s current -106.87% should be judged against Healthcare norms (sector average: 21.67%) and against BFRIW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -106.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Biofrontera- Warrants (27/10/2026), and consider following BFRIW for alerts when major investors trade the stock.
Biofrontera- Warrants (27/10/2026) is classified in the Healthcare sector. On ROE, it currently shows -106.87% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BFRIW with unrelated industries.
